Skip to main content
Clinical Trials/ITMCTR2022000064
ITMCTR2022000064
Not yet recruiting
Phase 1

A pragmatic randomized controlled clinical study of Tiaogan Huazhuo Decoction combined with exercise therapy in the treatment of metabolic associated fatty liver disease

China Academy of traditional Chinese medicine Guang an Men hospital0 sitesTBD

Overview

Phase
Phase 1
Intervention
Not specified
Conditions
metabolic associated fatty liver disease
Sponsor
China Academy of traditional Chinese medicine Guang an Men hospital
Status
Not yet recruiting
Last Updated
3 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
3 years ago
Study Type
Interventional study
Sex
All

Investigators

Sponsor
China Academy of traditional Chinese medicine Guang an Men hospital

Eligibility Criteria

Inclusion Criteria

  • ? Meet the diagnostic criteria of Chinese and Western medicine for MAFLD; ? Between 18 and 65 years old; ? Those who have good compliance, are willing to participate in the study, complete all procedures and follow\-up of the study, and sign informed consent.

Exclusion Criteria

  • ? Pregnant or lactating women; ? With serious diseases of important organs (such as heart, brain, lung and kidney); ? Clearly diagnosed as infectious hepatitis, liver biopsy has confirmed as cirrhosis, liver cancer patients; Or drug\-induced liver disease, genetic factors and other specific diseases that can lead to fatty liver; (4\) mentally and legally disabled patients; ? Suspected or had a history of drug abuse; Alcohol intake \=40g/d for males and \=20g/d for females; Or heavy drinking history within 2 weeks, equivalent to alcohol \> 80g/d; ? Known to be allergic to the drug components; ? Exercise contraindications; ? Had used antibiotics, living bacteria preparations, hormone drugs, immunosuppressants and other preparations that may affect intestinal flora in the past 1 month; Or have used hypoglycemic, lipid\-regulating and liver\-protecting drugs in recent 1 month; ? Patients with ALT\=3ULN or FPG\=7\.0mmol/L and no previous hypoglycemic drugs; ? Patients who are participating in clinical trials of other drugs; Or have participated in a drug clinical trial within the past one month.

Outcomes

Primary Outcomes

Not specified

Similar Trials